Italy Peptide Receptor Radionuclide Therapy (PRRT) Market to reach US$ 7.2 Million By 2027 | CAGR: 9.2%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, and Yttrium (Y-90)-based), by Indication (Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies), was valued at US$ 3.6 million in 2019 and is expected to witness a CAGR of 9.2% during the forecast period (2019 – 2027), as highlighted in a new report published by Coherent Market Insights.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/3139

Growth of the Italy peptide receptor radionuclide therapy market during the forecast period is expected to be driven by the rising drug approvals by regulatory bodies. For example, in 2018, Novartis received the U.S Food and Drug Administration (FDA) approval for lutetium (177Lu) oxodotreotide (Lutathera) for treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (NETs) (GEP-NETs).

Moreover, growth of the peptide receptor radionuclide therapy (PRRT) market in Italy is driven by the increasing number of cancer cases in the country. For example, according to European Union statistics related to cancer, in 2015, about 33,851 number of deaths were recorded due to lung cancer in Italy. This contributed to around 8% in total Europe region, in which the share of all deaths attributed to lung cancer was 3.4% among women and 7.2 % among men in Europe region.

Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3139

Furthermore, according to the World Health Organization (WHO), a total number of 409,808 cancer cases were recorded in 2018 in Italy, which included breast cancer, colorectal cancer, bladder cancer, lung cancer, prostate cancer, and several other type of cancers.

Browse 9 Market Data Tables and 12 Figures spread through 64 Pages and in-depth TOC on ‘Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, by Drug Type (Lutetium (Lu-177)-based, and Yttrium (Y-90)-based), by Indication (Gastroenteropancreatic Neuroendocrine Tumor), and by Distribution Channel (Hospital Pharmacies and Retail Pharmacies) – Italy Forecast to 2027’

To know the latest trends and insights related to Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Press Release, click the link below: http://bit.ly/3a3WSeS

Key Takeaways of the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market:

• The Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is expected to witness a CAGR of 9.2%during the forecast period due to the rising incidence of cancer and regulatory approvals.
• Among drug type, the Lutetium (Lu-177)-based segment is expected to account for a major revenue share by 2027 due to the rising strategic acquisitions by key players to expand their drug portfolio. For example, in 2017, Novartis acquired Advanced Accelerator Applications. With this acquisition, Novartis has expanded its product offering in the neuroendocrine business, through which the company offers the Lutetium (Lu-177)-based drug.
• Major player operating in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is Novartis International AG.

Have a Look at Related Research Insights:

Amitriptyline Market, By Strength (10 mg tablets, 25 mg tablets, 50 mg tablets, 75 mg tablets, 100 mg tablets, and 150 mg tablets), By Indication (Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), By Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Anti-aging Treatment Market, By Product Type (UV Absorbers, Anti-Wrinkle Products, Anti-Stretch Mark Products, Natural Products, and Others), By Technology (Botulinum Toxin Therapy, Dermabrasion, Microdermabrasion, Chemical Peels, Fractional Laser Skin Resurfacing, Dermal Fillers, and Nonablative Skin Rejuvenation), By End User (Hospitals, Skin Care Clinics, Homecare Settings, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.